Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA studyWilliam J. Sandborn, Geert D’Haens, Robert Clare et al.|Gut|2017Cited by 107
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II StudyGeert D’Haens, William J. Sandborn, Walter Reinisch et al.|Inflammatory Bowel Diseases|2021Cited by 16
OP024 Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II studyGeert D’Haens, William J. Sandborn, Walter Reinisch et al.|Journal of Crohn s and Colitis|2018Cited by 6
OP08 Long-term efficacy and pharmacodynamics of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) monoclonal antibody SHP647 in Crohn’s disease: the OPERA II studyG. D’Haens, W. Sandborn, Walter Reinisch et al.|Journal of Crohn s and Colitis|2019Cited by 3
Sa1746 - Long-Term Safety and Efficacy of the Anti-Madcam Monoclonal Antibody Shp647 for the Treatment of Crohn's Disease: The Opera II StudyGeert D’Haens, William J. Sandborn, Walter Reinisch et al.|Gastroenterology|2018Cited by 1